Management of residual masses in testicular germ cell tumors.

Abstract:

INTRODUCTION:About 50% of all patients with advanced testicular cancer demonstrate residual retroperitoneal or extraretroperitoneal masses. About two thirds of the masses harbour necrosis/fibrosis only whereas as about 10% and 40% harbour vital cancer or teratoma. Appropriate therapy will result in a high cure rate if performed properly. Areas covered: This review article covers the indication, the surgical technique and the oncological outcome of PC-RPLND and resection of extraretroperitoneal residual masses following chemotherapy in patients with advanced testis cancer. Expert commentary: Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) plays an integral part of the multimodality treatment in patients with advanced testicular germ cell tumours. Patients with nonseminomas, residual masses < 1cm and good prognosis can undergo active surveillance. In all other cases, PC-RPLND with or without resection of adjacent organs needs to be performed for curative intent. PC-RPLND requires a complex surgical approach and should be performed in experienced, tertiary referral centres only.

authors

Heidenreich A,Paffenholz P,Nestler T,Pfister D

doi

10.1080/14737140.2019.1580146

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

291-300

issue

4

eissn

1473-7140

issn

1744-8328

journal_volume

19

pub_type

杂志文章,评审
  • Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review.

    abstract::Introduction: Surgical treatment of thyroid cancer has become less aggressive but for many patients, the threshold for performing total thyroidectomy (TT), as opposed to thyroid lobectomy (TL), has remained unclear. Current American Thyroid Association (ATA) guidelines encourage more individualization of treatment opt...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850280

    authors: Guo MY,Wiseman JJ,Wiseman SM

    更新日期:2020-12-15 00:00:00

  • American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section.

    abstract::A number of important studies were presented at the CNS tumors section of the 2010 American Society of Oncology (ASCO) Annual Meeting. There was particular interest in a Phase II study showing that the mTOR inhibitor everolimus had significant activity in tuberous patients with subependymal giant cell astrocytomas. Tw...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/era.10.117

    authors: Wen PY

    更新日期:2010-09-01 00:00:00

  • Current concepts and future strategies in the management of intracranial germinoma.

    abstract::Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.856268

    authors: Kortmann RD

    更新日期:2014-01-01 00:00:00

  • Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy.

    abstract::Renal neoplasms exhibit a wide spectrum of molecular characteristics that are closely associated with their diverse morphologic manifestations and clinical behaviors. A wealth of information has been garnered via methodology ranging from classical cytogenetics to FISH and gene expression profiling; however, the exact ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.72

    authors: Cheng L,Williamson SR,Zhang S,Maclennan GT,Montironi R,Lopez-Beltran A

    更新日期:2010-06-01 00:00:00

  • Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.

    abstract::Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest as a bri...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2016.1168700

    authors: Woltsche N,Schwab C,Deinlein T,Hofmann-Wellenhof R,Zalaudek I

    更新日期:2016-05-01 00:00:00

  • Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.5.785

    authors: Lekakis L,de Lima M

    更新日期:2008-05-01 00:00:00

  • Latest developments in limb-salvage surgery in osteosarcoma.

    abstract::Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.225

    authors: Mangat KS,Jeys LM,Carter SR

    更新日期:2011-02-01 00:00:00

  • RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.

    abstract::Cancer immunotherapy aims at eliciting an immune response directed against tumor antigens to help fight off residual tumor cells and, thereby, improve the survival and quality of life of cancer patients. Different immunotherapeutic approaches share the use of dendritic cells (DCs) to present tumor-associated antigens ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,收录出版,评审

    doi:10.1586/14737140.9.1.97

    authors: Tyagi RK,Mangal S,Garg N,Sharma PK

    更新日期:2009-01-01 00:00:00

  • Cancer-related cachexia and oxidative stress: beyond current therapeutic options.

    abstract::Cancer-related anorexia/cachexia syndrome is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumor-derived catabolic factors, decreased food intake and probably additional unknown factors all play different roles. This review examines the...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.3.381

    authors: Mantovani G,Macciò A,Madeddu C,Massa E

    更新日期:2003-06-01 00:00:00

  • Breast cancer chemoprevention.

    abstract::According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemopr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.206

    authors: Gabriel EM,Jatoi I

    更新日期:2012-02-01 00:00:00

  • Oncogenomics: prospects for the future.

    abstract::Genomics has generated a wealth of data that is now being used to identify additional molecular alterations associated with cancer development. Mapping these alterations in the cancer genome is a critical first step in dissecting oncological pathways. There are two ways in which cancer research has changed in recent y...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.6.891

    authors: Sakatani T,Onyango P

    更新日期:2003-12-01 00:00:00

  • CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.

    abstract::Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1852934

    authors: Onesti CE,Jerusalem G

    更新日期:2020-12-13 00:00:00

  • Molecular changes in pancreatic cancer.

    abstract::As with many human malignancies, pancreatic cancer is a complex genetic disorder. Several thousand disease-associated alterations on the DNA, mRNA, miRNA and protein levels have been reported to date. Some of these alterations, including a number of gatekeeper mutations, which are of pre-eminent importance for the ons...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.107

    authors: Buchholz M,Gress TM

    更新日期:2009-10-01 00:00:00

  • Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.

    abstract:INTRODUCTION:In the last decade tyrosine kinase inhibitors (TKIs) have been employed for a wide range of hematological and solid tumors and today they represent a valid therapeutic option for different neoplasms. Among them, both sorafenib and lenvatinib were approved for the treatment of radioactive iodine (RAI) refra...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1390432

    authors: Felicetti F,Nervo A,Piovesan A,Berardelli R,Marchisio F,Gallo M,Arvat E

    更新日期:2017-12-01 00:00:00

  • Systemic treatment of vulvar cancer.

    abstract::Squamous cell carcinoma of the vulva is a rare disease, accounting for approximately 5% of cancers of the female genital tract. Standard therapy for early-stage vulvar cancer mainly comprises of surgery of the vulva and groins. In locally advanced or metastatic vulvar cancer, neoadjuvant or definitive chemoradiation i...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1037837

    authors: Mahner S,Prieske K,Grimm D,Trillsch F,Prieske S,von Amsberg G,Petersen C,Mueller V,Jaenicke F,Woelber L

    更新日期:2015-06-01 00:00:00

  • Improving the accuracy in prognosis for Burkitt lymphoma patients.

    abstract::A recent population-based study on 2000 adult patients with Burkitt lymphoma presented a novel score that takes into account age, race and clinical stage to prognosticate survival. The outcome of patients with Burkitt lymphoma has improved in the last decade, likely due to intensive chemotherapy regimens and anti-CD20...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.866042

    authors: Castillo JJ,Nadeem O

    更新日期:2014-02-01 00:00:00

  • Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era.

    abstract::Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.147

    authors: Ghavamian R,Hakimi AA

    更新日期:2009-12-01 00:00:00

  • Prodrugs for targeted cancer therapy.

    abstract::Introduction: Prodrugs have been used to improve the selectivity and efficacy of cancer therapy by targeting unique abnormal markers that are overexpressed by cancer cells and are absent in normal tissues. In this context, different strategies have been exploited and new ones are being developed each year. Areas cover...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1615890

    authors: Souza C,Pellosi DS,Tedesco AC

    更新日期:2019-06-01 00:00:00

  • Colorectal cancer stem cells and their implications for novel anticancer therapy.

    abstract::Anticancer therapy relies on targeting highly proliferative cells. Commonly used chemotherapy does not selectively target individual cancer cells. The identification of distinct cancer stem cells that have the unique ability to engraft tumors and maintain cancer self-renewal may prove vital in the development of novel...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.13.17

    authors: Klotz D

    更新日期:2013-04-01 00:00:00

  • Role of chemotherapy in the management of soft tissue sarcomas.

    abstract::Soft tissue sarcomas are a diverse group of rare tumors that comprise 1% of all cancers. Few randomized trials of chemotherapy have been performed but there is a clear role for agents such as doxorubicin and ifosfamide in the palliation of advanced disease. There is uncertainty as to whether sequential single-agent tr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.176

    authors: Krikelis D,Judson I

    更新日期:2010-02-01 00:00:00

  • Management of advanced bladder cancer in patients with impaired renal function.

    abstract::Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of these patients and is considered the standard of care. Nevertheless, 40-50% of patients have impaired renal function that p...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.197

    authors: Bournakis E,Dimopoulos MA,Bamias A

    更新日期:2011-06-01 00:00:00

  • A catalogue of treatment and technologies for malignant pleural mesothelioma.

    abstract::Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2016.1162100

    authors: Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

    更新日期:2016-01-01 00:00:00

  • MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer.

    abstract:INTRODUCTION:Tamoxifen, as an essential therapeutic tool in the treatment of estrogen receptor-positive breast cancer, has been available for the past three decades and is currently being utilized as a chemo-preventive agent for patients at high risk for breast carcinoma. However, the induction of chemo-resistance duri...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1340837

    authors: Merikhian P,Ghadirian R,Farahmand L,Mansouri S,Majidzadeh-A K

    更新日期:2017-07-01 00:00:00

  • β-adrenergic-blocking drugs and melanoma: current state of the art.

    abstract::The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and melanoma progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signaling can inhibit multiple cellular processes involved in melanoma progression and me...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.118

    authors: De Giorgi V,Grazzini M,Gandini S,Benemei S,Asbury CD,Marchionni N,Geppetti P

    更新日期:2012-11-01 00:00:00

  • Lymphocele: prevalence and management in gynecological malignancies.

    abstract::A lymphocele is a cystic mass that may occur in the retroperitoneum following a systematic pelvic and/or para-aortic lymphadenectomy. Lymphoceles may be the cause of severe morbidity, or rarely mortality. Symptomatic lymphoceles manifest with pain, compression of adjacent structures, lymphoedema, deep vein thrombosis ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.866043

    authors: Weinberger V,Cibula D,Zikan M

    更新日期:2014-03-01 00:00:00

  • Laparoscopic colorectal cancer surgery.

    abstract::Colorectal cancer remains the second most common cause of cancer death in the USA and western Europe, with more than 34,000 new cases per year in the UK alone. Annual expenditure is in excess of pounds sterling 300 million, required for surgical, adjuvant and palliative treatment. Laparoscopic colorectal surgery has y...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.4.484

    authors: Macafee DA,Maxwell-Armstrong C,Scholefield JH

    更新日期:2003-08-01 00:00:00

  • The evolving role of receptors as predictive biomarkers for metastatic breast cancer.

    abstract:INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1552138

    authors: Martínez-Pérez C,Turnbull AK,Dixon JM

    更新日期:2019-02-01 00:00:00

  • Antineoplastic therapy-induced pulmonary toxicity.

    abstract::Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.817684

    authors: Sadowska AM,Specenier P,Germonpre P,Peeters M

    更新日期:2013-08-01 00:00:00

  • Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond.

    abstract::Since its introduction almost 40 years ago, intravesical BCG for non-muscle invasive bladder cancer remains one of the most successful cancer immunotherapies. However, up to 40% of patients will progress after BCG therapy and develop invasive bladder cancer. Despite its extensive clinical use, we are only beginning to...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1015419

    authors: Wu Y,Enting D,Rudman S,Chowdhury S

    更新日期:2015-05-01 00:00:00

  • Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.

    abstract::Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.3.437

    authors: Kose MF,Meydanli MM,Tulunay G

    更新日期:2006-03-01 00:00:00